IOMERVU is a newly approved radiographic contrast agent designed to enhance the visibility of blood vessels and organs during medical imaging procedures. It is used in both adults and children for intra-arterial and intravenous imaging, offering precise diagnostics for various medical conditions. IOMERVU was approved on November 27, 2024.
What is the name of the drug, and what does it do?
IOMERVU (pronounced eye-oh-MER-voo) is a contrast agent used during imaging procedures like CT scans and angiography. It works by temporarily highlighting blood vessels, organs, or other areas of the body to make them visible on X-rays and other scans.
How does it work?
IOMERVU contains iodine, which absorbs X-rays, making specific structures in the body stand out during imaging. Once administered into a vein or artery, it travels to the area being examined, creating clearer images for accurate diagnosis.
What did the research discover?
Clinical trials evaluated IOMERVU in over 4,600 adult patients across various imaging procedures. It was shown to provide excellent image clarity, allowing healthcare providers to diagnose conditions effectively. For example, during coronary arteriography, 93% to 100% of patients achieved adequate visualization. In pediatric trials, the drug demonstrated similar success rates, confirming its safety and effectiveness across all age groups.
What are some of the side effects?
The most common side effects of IOMERVU include:
- Feeling hot
- Headache
- Nausea
- Chest pain
- Back pain
- Vomiting
Rare but severe reactions include hypersensitivity reactions, kidney injury, and cardiovascular disturbances.
What are the dosage recommendations, and how is it prescribed?
IOMERVU is available in various concentrations, depending on the imaging procedure. The dosage is individualized based on factors like patient age, weight, and the area being examined. It is administered via injection in a hospital or imaging center under the supervision of medical professionals.
Source
Bracco Diagnostics Inc. Prescribing information for IOMERVU. November 2024. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216017s000,216017s000lbl.pdf
